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Abstract [word count: 250/250] 45 
Background: Chronic obstructive pulmonary disease (COPD) is commonly managed by family 46 
physicians, but little is known about specifics of management and how this may be improved.  47 
The Advancing the Patient Experience in COPD (APEX COPD) registry will be the first U.S. 48 
primary care, health system-based registry following patients diagnosed with COPD 49 
longitudinally, using a standardized set of variables to investigate how patients are managed 50 
in real-life and assess outcomes of various management strategies.  51 
Objective: Gaining expert consensus on a standardized list of variables to capture in the APEX 52 
COPD registry.  53 
Methods: A modified, Delphi process was used to reach consensus on which data to collect in 54 
the registry from electronic health records (EHRs), patient-reported information (PRI) and 55 
patient-reported outcomes (PRO), and by physicians during subsequent office visits. The 56 
Delphi panel comprised 14 primary care and specialty COPD experts from the U.S. and 57 
internationally. The process consisted of three iterative rounds. Responses were collected 58 
electronically. 59 
Results: Of the initial 195 variables considered, consensus was reached to include up to 115 60 
EHR variables, 34 PRI/PRO variables and five office-visit variables in the APEX COPD registry. 61 
These should include information on symptom burden, diagnosis, COPD exacerbations, lung 62 
function, quality-of-life, comorbidities, smoking status/history, treatment specifics (including 63 
side effects), inhaler management, and patient education/self-management. 64 
Conclusions: COPD experts agreed upon the core variables to collect from EHR data and from 65 
patients to populate the APEX COPD registry. Data will eventually be integrated, standardized 66 






Chronic obstructive pulmonary disease (COPD) is managed predominantly by family 70 
physicians, but little is known about how this prevalent disease is managed in primary care, 71 
or how primary care management in the U.S. may be improved. Management of this disease 72 
is daunting when one considers the sheer size of the population (16 million U.S. adults and 73 
rising),1,2 the continuing rise in COPD-related mortality,3,4 the high symptom burden 74 
experienced by patients,5 and the cost to the U.S. economy (predicted $50 billion by 2020).6  75 
The prevalence and burden of COPD are predicted to increase over the coming decades due 76 
to continued exposure to COPD risk factors (tobacco smoking, air pollution) and aging of the 77 
population.7 Although the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 78 
strategy provides clear strategies for COPD diagnosis and management,8 they are often not 79 
fully understood nor implemented in primary care practice.9 COPD remains a disease which 80 
is under- and mis-diagnosed, resulting in delayed and/or sub-optimal disease management.10–81 
12 The question remains, how do we ensure optimum management of COPD patients in 82 
primary care? 83 
 84 
Both primary care- and patient-related factors make this a difficult question to answer. The 85 
issues in primary care include a reticence to diagnose COPD in already multi-morbid patients, 86 
the temptation to prescribe antibiotics for patients who present with chest 87 
infections/bronchitis rather than delving into a COPD diagnosis protocol, and a lack of 88 
understanding (or indeed, availability) of spirometry.12 The issue of COPD under-diagnosis 89 
may be further exacerbated by failure to recognize GOLD Group C patients. These patients 90 
are not particularly symptomatic but do experience a substantial number of chest infections.8 91 




specialist referral. These issues represent significant hurdles to optimized COPD management 93 
in primary care, since establishing and acting on an early diagnosis of COPD is a critical step 94 
in reducing the extensive morbidity and mortality of this disease. Large-scale efforts to 95 
promote awareness of COPD and encourage early diagnosis have been undertaken, to tackle 96 
these issues and others in COPD management (e.g. the National Lung Health Education 97 
Program in the U.S.). Patient-related hurdles to optimized COPD management include disease 98 
denial (lack of understanding, under-estimation of disease impact), poor adherence, lack of 99 
patient engagement and empowerment, variable disease presenting patterns, and cost-100 
related issues.12 101 
 102 
In order to improve the management of COPD in primary care, it is first necessary to describe 103 
the patient population in a standardized way, using variables which are clinically relevant, and 104 
which can be practically collected and monitored longitudinally. This information should be 105 
relevant to both physicians and patients to encourage therapeutic shared decision-making 106 
and ultimately better adherence. A COPD registry is one way to achieve these aims. Registries 107 
are well-established tools for tracking and reporting epidemiological disease trends that 108 
enable treatment benefits and risks that can be longitudinally monitored. They are also useful 109 
to track the natural progression of disease, which may be particularly relevant in COPD where 110 
progression is slow, and patterns can be difficult to spot. They have the potential to improve 111 
diagnostics and be used to inform treatment algorithms.13 Although both national and 112 
regional COPD registries and patient cohorts do already exist in the U.S. (e.g. the Genetic 113 
Epidemiology of COPD (COPDGene),14 the COPD Patient-Powered Research Network (COPD 114 
PPRN),15 and others hosted by universities and healthcare networks), none are based in 115 




missing the milder and moderate severity patients. None have captured information on how 117 
patients are managed in primary care in real-life.  118 
 119 
The Advancing the Patient Experience in COPD (APEX COPD) registry 120 
(https://www.apexcopd.org/) will be the first U.S. primary care health system-based registry, 121 
designed to follow these patients longitudinally, investigate how they are managed in a real-122 
life setting and the consequence(s) of various management strategies. The overall aim is to 123 
improve primary care for patients with a diagnosis of COPD by capturing clinically-relevant 124 
and high-quality data using a standardized set of variables, from multiple sources, in sufficient 125 
numbers of patients to ensure representativeness to the wider COPD population, and to 126 
answer key research questions relating to COPD in primary care. The registry plans to bring 127 
together information captured in electronic health records (EHRs), and information provided 128 
by patients themselves (i.e. from questionnaires and during office visits). This will be achieved 129 
using standardized data collection, guided by COPD clinicians both in primary and specialist 130 
care. Further, the registry may identify patterns of healthcare before a diagnosis,16and has 131 
the potential to identify new COPD phenotypes.  132 
 133 
The aim of the Delphi exercise described in this article was to gain expert consensus on a 134 
standardized list of variables on demographic, disease monitoring and treatment variables to 135 
establish the APEX COPD registry. Selection of these variables was dictated not only by clinical 136 
relevance; it was also important that variables were already known to family physicians and 137 
that it was practical and feasible to collect them in primary care. 138 
 139 






This study used a modified, three-round Delphi process to achieve consensus on the core 143 
variables to be collected in the APEX COPD registry.17 Variables were initially selected from 144 
relevant COPD guidelines and recommendations to give all potentially clinically relevant 145 
options, and subsequently refined by the panel to the items desired for inclusion in the 146 
registry. 147 
 148 
Panel selection 149 
The APEX COPD Delphi panel consisted of appropriately qualified and experienced individuals 150 
in the field of COPD and primary care, capable of providing critical and informed input. This 151 
panel included 14 experts in primary and specialist care from the US and internationally – five 152 
family physicians, three pulmonologists, six respiratory researchers (five of whom had 153 
substantial prior experience as family physicians), with >70% of panel members based in the 154 
U.S.  (Table E1). The panel members met two or more of the following criteria: 155 
1. Evidence of relevant COPD research published in high-ranking peer-reviewed journals 156 
(e.g. high number of citations and research items). 157 
2. A history of participation in the development and/or management of one or more 158 
respiratory registries or cohorts, epidemiological databases, and scientific congress 159 
committees in a country and/or internationally. 160 
3. Experience as a medical clinician (e.g. physician or nurse) with an interest in advancing 161 





Modified Delphi process 164 
A modified Delphi process was used to reach consensus on which data to collect into the 165 
registry from EHR, patient reported information/patient reported outcomes (PRI/PROs), and 166 
at consultation.18The process consisted of three iterative rounds (Round 1 (R1), Round 2 (R2) 167 
and Round 3 (R3); Figure 1). 168 
 169 
Each Delphi panel member was issued an electronic APEX COPD Excel workbook to review, 170 
provide suggestions and vote, in order to select core variables. Members then returned the 171 
completed Delphi workbooks to the APEX COPD administrator within a four-week time 172 
period. The Delphi administrator directly corresponded with all panel members individually 173 
to ensure anonymity of replies and was responsible for disseminating workbooks and result 174 
summaries for each round. 175 
 176 
Delphi Round 1 177 
The Delphi workbook (APEX COPD Workbook Round 1) was developed initially by 178 
consolidating variables from current guidelines and recommendations: the American Thoracic 179 
Society (ATS) and European Respiratory Society (ERS) joint guidelines, COPD Foundation, and 180 
GOLD.18-25 Variables under consideration included: 181 
• Patient demographics. 182 
• Medical history, symptoms (COPD-relevant), prior exacerbations, exposure, and 183 
comorbidities. 184 
• COPD treatment and management, including medications and side effects (such as those 185 




vaccinations, referrals, surgery, rehabilitation, smoking cessation, and other non-187 
pharmacological strategies. 188 
• Patient-reported information and outcomes including health status scores (COPD 189 
Assessment Test (CAT), modified Medical Research Council (mMRC) dyspnea scale), and 190 
questionnaires (e.g. inhaler satisfaction questionnaire, and Test of Adherence to Inhalers 191 
(TAI)) to measure respiratory inhaler device satisfaction and inhaler adherence. 192 
• Medical test/investigations, including spirometry, electrocardiogram, and biomarkers 193 
(blood eosinophils, IgE, and fractional exhaled nitric oxide (FeNO) where possible). 194 
The workbook comprised a two-tab Excel spreadsheet: 195 
• On tab one, displaying the potential core list (Table 1), panel members were required to 196 
select an option (“Yes” or “No”) via a drop-down menu for each variable, indicating 197 
whether or not they concurred that the variable would be part of the APEX COPD registry 198 
core variable list. 199 
• On tab two, panel members were encouraged to nominate variables from the “additional” 200 
variable list (Table 2) and/or propose new variables (“Suggested”). During this round, 201 
experts were also encouraged to provide comments for excluding or including variables. 202 
At round closure, the Delphi administrator anonymized all returned workbooks and compiled 203 
all replies to tabulate frequency of responses, “Yes” and “No,” for each variable on the lists. 204 
Variable consensus was evaluated using summary statistics (frequency counts) generated 205 
with the Microsoft Excel V16.27 statistical package. Delphi R1 consensus rules for each 206 
variable assessed by the panel were as follows: Keep (>66% ‘yes’); undecided (≥50 to ≤66% 207 
'yes'); exclude (<50% ‘yes’). 208 
 209 




Delphi Round two 211 
All variables from R1 as well as “suggested” variables were included in a single tab in the R2 212 
workbook and the expert panel was requested to engage in a similar voting process for Delphi 213 
R2. The Delphi R1 summary results and panel member comments (“Comments”) were 214 
anonymized and provided in the R2 workbook to facilitate an informed decision. Delphi R2 215 
was divided into 2 parts: 216 
• Round 2a: Each variable that received a 66% or more consensus from the Delphi panel in 217 
R2 was moved to a second phase of analysis (R2b). Other variables were excluded from 218 
the APEX COPD registry core variable list. 219 
• Round 2b: Variables moved to R2b were analyzed more specifically to determine which 220 
data sources they should be collected from (EHR, PRI/PRO, or at the doctor’s office (i.e. 221 
point of care (PoC))). 222 
Delphi R2 consensus rules for each variable assessed by the panel were as follows: Keep (≥66% 223 
consensus); undecided (40 to 65% consensus); exclude (<40% consensus). Additionally, all 224 
excluded variables from R2 were vetted by the APEX COPD Operational Management Group 225 
(AOMG; Table E2). If excluded variables were considered key to COPD primary care by the 226 
AOMG, they were re-included for review in R3. 227 
 228 
Delphi Round three 229 
The Delphi panel also took part in a similar voting process for Delphi R3 via a third 230 
electronically distributed workbook (The APEX COPD Delphi Workbook Round three). The 231 
Delphi R2 summary results and panel member comments (“Comments”) were anonymized 232 
and provided in the R3 workbook to facilitate an informed decision. R2 “Undecided” and 233 




rules for each variable assessed by the panel were as follows: keep (≥66% consensus); 235 
undecided (40 to 65% consensus); exclude (<40% consensus). All undecided and excluded 236 
variables from R3 were vetted by the AOMG. If these variables were considered key to COPD 237 
primary care by the AOMG, they were included in the final core variable list. 238 
 239 





Delphi Round one 242 
In R1, the expert panel voted on 189 clinical COPD variables belonging to the categories of 243 
demographics, disease monitoring, and treatment (Table E3). Overall, 149 of the variables 244 
received >66% consensus to keep, 25 were undecided (50% to 66% consensus), and 15 were 245 
recommended to exclude (receiving <50% consensus) (Table E4). All 189 variables were 246 
entered into voting round two. Six “suggested” variables recommended by the panel were 247 
also added bringing the total to 195 variables to proceed to R2. 248 
 249 
Delphi Round two 250 
After voting R2, 25 of the 195 variables were excluded from collection into the registry and 251 
170 were confirmed for collection (Table E5, Part A). Of the 170 confirmed variables the 252 
Delphi panel recommended that 115 be collected from EHR, and 16 via PRI/PRO. At this stage, 253 
no variables were confirmed for collection by clinicians during a visit. (Table E5, Part B). 254 
Undecided variables were entered into Delphi Round 3. Four undecided PRI/PRO variables 255 
from R2a were re-included for review in R3. These were: 256 
• Poor appetite: an important factor used in conjunction with other cancer indicators which 257 
received consensus votes to be included for collection. 258 
• Easy bruising: specific types of physiological side effects were not specified for voting; 259 
bruising is a common and important side effect to assess in patients receiving inhaled 260 
corticosteroid (ICS). 261 
• Pain (headache and muscle): specific types of pain as side effects were not specified for 262 
voting; muscle pain and headaches are common and preventable effects to assess in 263 




• Low birth weight: an important childhood risk factor which may not be recorded in 265 
patients’ EHR. 266 
One excluded PoC variable from R2a was re-included for review in R3. This was: 267 
• Inhaler technique assessment: important for interpretation of peak inspiratory flow rate 268 
(PIFR) which received a consensus vote to be included for collection from the EHR and an 269 
undecided vote to be collected during the office visit. 270 
 271 
Delphi Round three 272 
A final round of voting (R3) was undertaken to vote on ‘undecided’ PRI/PRO and PoC variables 273 
from R2. A total of 13 PRI/PRO and two PoC variables were kept on consensus. Of the 274 
remaining 27 undecided PRI/PRO variables at R3, three were confirmed for collection by the 275 
AOMG (Table E6). The reasons were:  276 
• Pulmonary rehabilitation: critical for prevention of disease progression and management 277 
• Influenza vaccine: can be administered by an external provider and therefore may not be 278 
collected in patients’ EHR. This information is critical for informing preventative care. 279 
• Oral treatment side effect (candidiasis): specific types of oral side effects not specified for 280 
voting; oral candidiasis is a common and important side effect to assess in patients 281 
receiving ICS. 282 
Two additional PRI/PRO variables excluded in R2b were vetted and included in the final core 283 
variable list. These were: 284 
• Asthma diagnosis (age of onset): decision to collect via PRI/PRO in addition to EHR to 285 




• Physiological treatment side effect (easy bruising): specific types of physiological side 287 
effects were not specified for voting; bruising is a common and important side effect to 288 
assess in patients receiving ICS. 289 
Of the three undecided variables for collection during the office visit at R3, three were 290 
confirmed for collection by the AOMG. These were:  291 
• Number of severe exacerbations in the past year,  292 
• Forced expiratory volume in one second (FEV1) post-bronchodilator, and 293 
• Forced vital capacity (FVC) post-bronchodilator  294 
These were all considered critical for COPD management and will be collected at PoC only if 295 
missing from EHR and PRI/PRO. 296 
The core variables that achieved consensus via the closely guided three rounds of Delphi were 297 
included in the final core variable list (Table 3).  298 
 299 





Using the knowledge and experience of an international panel of COPD experts, workable 302 
criteria for registry purposes, a standardized core set of variables, and a potential method to 303 
unify data for COPD in the U.S. were generated and agreed to by consensus. All potential 304 
variables underwent a rigorous, stepwise consensus process to ensure the collection of the 305 
minimum required information to effectively and practically study the diagnosis and 306 
management of patients with COPD. Of the initially circulated “potential core” and “suggest” 307 
variables circulated, up to 115 were selected from existing EHR for integration in the APEX 308 
COPD registry, 34 PRI/PRO variables and five variables to be collected during office visits. 309 
These selected variables fall into three broad categories (i.e. demographics, disease 310 
monitoring, and treatment), and should include information on diagnosis, exacerbations, 311 
symptoms, lung function, and quality of life, co-morbidities, smoking history, treatment 312 
specifics (including side effects), inhaler management (including inhaler technique) and 313 
education/self-management. They have been selected not only due to their clinical relevance 314 
and usefulness to family doctors and patients (Table 3) but also with feasibility, familiarity 315 
and practicality of collection in mind. This will ensure that the APEX COPD registry will be an 316 
asset to family doctors; a tool to identify how patients with COPD are managed in real life, in 317 
a population rarely included in randomized controlled trials Following ratification of data 318 
collection, the registry plans to integrate information from multiple sources with maximal 319 
efficiency and present it to clinicians and patients in a structured and clinically useful format, 320 
with the aim of improving primary care for patients diagnosed with COPD. Data from the 321 
registry will also be used to answer key research questions relating to COPD in primary care, 322 




new research proposals will be continuously updated via the APEX COPD website 324 
(https://www.apexcopd.org/). 325 
The panel-approved APEX COPD registry variables were chosen to ensure a comprehensive 326 
description of patients diagnosed with COPD and managed in real-life clinical practice among 327 
family physicians in the U.S. Collection of baseline information on diagnosis, infection, 328 
exacerbations, severity classification, health status, and treatment-/co-morbidity-patterns 329 
will provide a snapshot of clinical phenotypes of COPD, a better understanding of how 330 
patients are diagnosed and managed in primary care (e.g. use of spirometry), an estimation 331 
of the burden of disease (including the corticosteroid burden), and an assessment of whether 332 
diagnoses and severity classifications are correct and treatment is appropriate (compared to 333 
guideline recommendations).8 Appropriate variables will be assessed longitudinally to 334 
examine their impact on disease progression and treatment outcomes. For example, data 335 
may be assessed to (i) compare the clinical, safety and cost-effectiveness of current COPD 336 
treatments, (ii) describe treatment changes over time (and the reasons for those changes), 337 
(iii) assess the impact of inhaler technique and inhaler type on key outcomes, (iv) analyze risk 338 
factors associated with disease progression and healthcare utilization and (iv) predict 339 
response to treatment (e.g. biomarkers). 340 
 341 
As well as the collection of key COPD variables from multiple sources, the APEX COPD registry 342 
has numerous other assets, including (i) its size and scope, (ii) innovative use of technology to 343 
collect high quality data, (iii) inclusion of clinical and database management expertise, (iv) 344 
inclusion of expertise on gathering patient reported information (v) an integrated 345 
communication strategy and (vi) the organizational structure to oversee the initiative and 346 




diagnosed with COPD, with a wide geographic coverage throughout the U.S, benefiting from 348 
both scale and generalizability to the wider COPD population. Patients included will have a 349 
diagnostic, monitoring, or review code for COPD prior to or at consultation and be aged ≥35 350 
years at COPD diagnosis. Data collected by APEX COPD registry will be maintained as a limited 351 
dataset in the APEX COPD database. Data will be completely de-identified, at the individual 352 
level, and anonymized when providing subsets of data for research purposes. Electronic data 353 
capture (EDC) systems will be utilized to capture data directly from EHR, which may already 354 
include valuable information on symptoms, lung function, COPD staging, pharmacologic 355 
treatment, co-morbidities, and exacerbations. Use of an existing data resource to populate 356 
the APEX COPD registry precludes the need for lengthy additional data collection at the PoC, 357 
which will improve efficiency, reduce workload, time, and cost, and enhance the quality of 358 
data collected.  359 
 360 
Expertise is embedded into the initiative, including the panel of 14 COPD experts on the APEX 361 
COPD Steering Committee, recruitment of primary care consultants experienced in COPD 362 
management, incorporation of a dedicated communications team to disseminate key 363 
research findings and partnership with experts in PRI and PRO (COPD Foundation and the 364 
American Academy of Family Physicians), and database management and registry delivery 365 
(DARTNet Institute, CO, US). Communication of APEX COPD registry research findings will also 366 
be facilitated via regular publication in peer-reviewed journals and dissemination of findings 367 
at international and regional scientific meetings. The APEX COPD registry is overseen by five 368 
bodies (OPC Global, The Respiratory Effectiveness Group, the Anonymized Data Ethics & 369 
Protocol Transparency Committee, the American Academy of Family Physicians, and the APEX 370 




ensuring APEX COPD research is ethical, clinically appropriate and continues to bring genuine 372 
value to physicians who manage COPD in real-life clinical practice, and to patients who live 373 
with COPD.  374 
Strengths and weaknesses 375 
Fourteen Delphi panel members from four countries (>70% US-based experts) participated in 376 
one or more Delphi rounds, to allow for broad consensus to be obtained, and to ensure 377 
recommendations were pertinent not only to the U.S., but also maintained applicability 378 
beyond U.S. borders. This approach dilutes the opinion of a single expert, so bias is decreased 379 
and diversity within the expert panel is maximized. Panel members were chosen for their 380 
expertise in the research field, and relevant medical practice and experience. The anonymity 381 
of the survey ensured all opinions were given equal weight and consideration. The Delphi 382 
process was carried out online, to facilitate ease of yes/no voting for each variable, as well as 383 
rapid and accurate vote counting and classification (i.e. yes, no, undecided) at the end of each 384 
Round. It also facilitated rapid and open communication among the COPD experts. The results 385 
covered a wide range of areas where consensus was achieved. Although the study employed 386 
a relatively small Delphi panel, recent studies have found that reliable outcomes can be 387 
obtained with a relatively small number of Delphi experts.27 The Delphi panel was also not 388 
fully representative of the diversity of stakeholders involved in respiratory care at the primary 389 
care level. In particular, the opinions of payers and patients were not solicited. Another 390 
limitation of the study is that the response rate was not 100%; a total of 13 of 14 experts 391 
(93%) responded to all three Delphi rounds. However, there was consistency in the number 392 
of experts who participated in each round (R1 = 93%; R2 = 100%; R3 = 100%), which ensured 393 





In conclusion, COPD experts have agreed on core variables to collect in the APEX COPD 396 
registry. The majority of these variables will be extracted from EHRs but will also include 397 
PRI/PRO and PoC data from 3,000+ patients diagnosed with COPD across the U.S. Data will be 398 
integrated, standardized and stored in the APEX COPD database and made available for COPD-399 
related research. It will be used to analyze COPD natural history as well as clinical, safety and 400 
cost-effectiveness of current COPD treatments in primary care across the US. 401 
 402 
Acknowledgments 403 
The author(s) meet criteria for authorship as recommended by the International Committee 404 
of Medical Journal Editors (ICMJE). We thank Dr. Alvaro Aranda (Hospital Auxilio Mutuo, San 405 
Juan, Puerto Rico) for his scientific and clinical contributions during the drafting of this 406 
manuscript. We also thank Ms. Audrey Ang for editorial assistance, Ms. Bronte Sawyer for 407 
project coordination, and Dr. Lisa Buttle for assistance with drafting the article. Dr. Ruth B. 408 
Murray is acknowledged for her substantial contribution to the interpretation, summarization 409 
and presentation of data in this article and significant intellectual input to the manuscript. 410 
She has provided her final approval of the version to be published and agreed to be 411 
accountable for all aspects of the work in ensuring that questions related to the accuracy or 412 
integrity of any part of the work are appropriately investigated and resolved. Dr. Ruth B. 413 
Murray is the founder and director of Medscript Ltd., a company that provided writing and 414 
editorial support for APEX COPD publications. 415 
Declaration of Interest 416 
Chelsea Edwards is an employee of the company Optimum Patient Care, which is a co-founder 417 




Alan Kaplan is a member of the advisory board of, or speakers bureau for, Astra Zeneca, 419 
Boehringer Ingelheim, Grifols, GlaxoSmithKline, Merck Frosst, Novo Nordisk, Novartis, 420 
Paladdin, Pfizer, Purdue, Sanofi, Teva, and Trudel. 421 
Barbara Yawn has served on COPD-related advisory boards for GlaxoSmithKline, AstraZeneca, 422 
Novartis, and Boehringer Ingelheim, and received COPD-related investigator-initiated 423 
research funds from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Novartis. 424 
Janwillem W. H. Kocks declares grants and personal fees from AstraZeneca, Boehringer 425 
Ingelheim, GlaxoSmithKline, and Novartis, and grants from Chiesi, Mundipharma and Teva. 426 
Lakmini Bulathsinhala is an employee of the company Optimum Patient Care, which is a co-427 
founder of the APEX COPD initiative. 428 
Victoria Carter is an employee of the company Optimum Patient Care, which is a co-founder 429 
of the APEX COPD initiative. 430 
Ku-Lang Chang declares no conflict of interest. 431 
Chester Fox declares no conflict of interest. 432 
Gokul Gopalan is a former employee of the company Boehringer Ingelheim, which is a co-433 
founder of the APEX COPD initiative and current employee of Vertex Pharmaceuticals. 434 
MeiLan Han reports consulting for Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca, 435 
and research support from Novartis and Sunovion. 436 
Maja Kruszyk is an employee of the company Optimum Patient Care, which is a co-founder of 437 




Chantal Le Lievre is an employee of the company Optimum Patient Care, which is a co-founder 439 
of the APEX COPD initiative. 440 
Cathy Mahle is an employee of the company Boehringer Ingelheim, which is a co-founder of 441 
the APEX COPD initiative. 442 
Barry Make reports funding from the NHLBI for the COPDGene study; grants and medical 443 
advisory boards from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; 444 
personal fees for DSMB from Spiration and Shire/Baxalta; CME personal fees from WebMD, 445 
National Jewish Health, American College of Chest Physicians, Projects in Knowledge, Hybrid 446 
Communications, SPIRE Learning, Ultimate Medical Academy, Catamount Medical, Eastern 447 
Pulmonary Society, Catamount Medical Communications  Medscape, Eastern VA Medical 448 
Center, Academy Continued Healthcare Learning, and Mt. Sinai Medical Center; royalites 449 
from Up-To-Date; medical advisory boards from Novartis, Phillips, Third Pole, Science 24/7, 450 
and Vernoa; grants from Pearl; outside the submitted work. 451 
Wilson Pace is on the advisory board for Mylan; stock from Novo Nordisk, Pfizer, Novartis, 452 
Johnson and Johnson, Stryker, Amgen, Gilead, and Sanofi. 453 
Chris Price is an employee of the company Optimum Patient Care, which is a co-founder of 454 
the APEX COPD initiative. 455 
Asif Shaikh is an employee of the company Boehringer Ingelheim, which is a co-founder of the 456 
APEX COPD initiative. 457 
Neil Skolnik is on advisory boards for AstraZeneca, Teva, Lilly, Boehringer Ingelheim, Sanofi, 458 




lectures/speaking engagements from AstraZeneca and Boehringer Ingelheim; Research 460 
Support from Sanofi, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. 461 
David Price has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, 462 
Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva 463 
Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, 464 
Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva 465 
Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated 466 
studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from 467 
AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, 468 
Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva 469 
Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking 470 
engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, 471 
Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva 472 
Pharmaceuticals; payment for the development of educational materials from Mundipharma, 473 
Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, 474 
Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient 475 
enrolment or completion of research from Novartis; stock/stock options from AKL Research 476 
and Development Ltd which produces phytopharmaceuticals; owns 74% of the social 477 
enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and 478 
Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees 479 
of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. 480 





1.  Wheaton AG, Cunningham TJ, Ford ES, Croft JB, Centers for Disease Control and 483 
Prevention (CDC). Employment and activity limitations among adults with chronic 484 
obstructive pulmonary disease--United States, 2013. MMWR Morb Mortal Wkly Rep. 485 
2015;64(11):289-295. 486 
2.  Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung 487 
function in adults in the United States: data from the National Health and Nutrition 488 
Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689. 489 
doi:10.1001/archinte.160.11.1683 490 
3.  Ma J, Ward EM, Siegel RL, Jemal A. Temporal Trends in Mortality in the United States, 491 
1969-2013. JAMA. 2015;314(16):1731-1739. doi:10.1001/jama.2015.12319 492 
4.  Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of 493 
death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of 494 
Disease Study 2010. Lancet Lond Engl. 2012;380(9859):2095-2128. doi:10.1016/S0140-495 
6736(12)61728-0 496 
5.  Murray CJL, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of 497 
diseases, injuries, and risk factors. JAMA. 2013;310(6):591-608. 498 
doi:10.1001/jama.2013.13805 499 
6.  Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific 500 
medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States 501 





7.  Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 504 
2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442 505 
8.  Global Initiative for Obstructive Lung Disease. Pocket guide to COPD diagnosis, 506 
managment and prevention. 2019 update. https://goldcopd.org/wp-507 
content/uploads/2018/11/GOLD-2019-POCKET-GUIDE-FINAL_WMS.pdf 508 
9.  Criner RN, Han MK. COPD Care in the 21st Century: A Public Health Priority. Respir Care. 509 
2018;63(5):591-600. doi:10.4187/respcare.06276 510 
10.  Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and Overdiagnosis of Chronic 511 
Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;198(9):1130-1139. 512 
doi:10.1164/rccm.201804-0621CI 513 
11.  Miller MR, Levy ML. Chronic obstructive pulmonary disease: missed diagnosis versus 514 
misdiagnosis. BMJ. 2015;351:h3021. doi:10.1136/bmj.h3021 515 
12.  Cooke CE, Sidel M, Belletti DA, Fuhlbrigge AL. Review: clinical inertia in the management 516 
of chronic obstructive pulmonary disease. COPD. 2012;9(1):73-80. 517 
doi:10.3109/15412555.2011.631957 518 
13.  Gliklich RE, Dreyer NA, Leavy MB, eds. Registries for Evaluating Patient Outcomes: A 519 
User’s Guide. 3rd ed. Agency for Healthcare Research and Quality (US); 2014. 520 
http://www.ncbi.nlm.nih.gov/books/NBK208616/ 521 
14.  Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) 522 




15.  COPD Patient-Powered Research Network (PPRN). 524 
https://www.copdfoundation.org/Research/COPD-Patient-Powered-Research-525 
Network/COPD-PPRN-Why-you-should-enroll.aspx 526 
16.  Jones RCM, Price D, Ryan D, et al. Opportunities to diagnose chronic obstructive 527 
pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. 528 
Lancet Respir Med. 2014;2(4):267-276. doi:10.1016/S2213-2600(14)70008-6 529 
17.  Pill, J. The Delphi method: substance, context, a critique and an annotated bibliography. 530 
Socioecon Plann Sci. 1971;5:57-71. 531 
18.  Eubank BH, Mohtadi NG, Lafave MR, et al. Using the modified Delphi method to establish 532 
clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. 533 
BMC Med Res Methodol. 2016;16:56. doi:10.1186/s12874-016-0165-8 534 
19.  Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of 535 
patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 536 
2004;23(6):932-946. doi:10.1183/09031936.04.00014304 537 
20.  Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic 538 
obstructive pulmonary disease: a clinical practice guideline from the American College of 539 
Physicians. Ann Intern Med. 2007;147(9):633-638. 540 
21.  Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic 541 
obstructive pulmonary disease: a clinical practice guideline update from the American 542 




and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191. 544 
doi:10.7326/0003-4819-155-3-201108020-00008 545 
22.  Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a 546 
European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 547 
2017;50(3). doi:10.1183/13993003.02265-2016 548 
23.  Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: 549 
a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 550 
2017;49(3). doi:10.1183/13993003.00791-2016 551 
24.  Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD Foundation Guide for 552 
Diagnosis and Management of COPD, recommendations of the COPD Foundation. COPD. 553 
2013;10(3):378-389. doi:10.3109/15412555.2013.801309 554 
25.  Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the 555 
diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med 556 
J Aust. 2017;207(10):436-442. doi:10.5694/mja17.00686 557 
26.  Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, 558 
management, and prevention of chronic obstructive pulmonary disease. 2018. 2018. 559 
https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-560 
Nov_WMS.pdf 561 
27.  Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: 562 





28.  van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness 565 
of  LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J J 566 
Gen Pract Airw Group. 2012;21(1):101-108. doi:10.4104/pcrj.2011.00102 567 
29.  de Marco R, Accordini S, Marcon A, et al. Risk factors for chronic obstructive pulmonary 568 
disease in a European cohort of young adults. Am J Respir Crit Care Med. 2011;183(7):891-569 
897. doi:10.1164/rccm.201007-1125OC 570 
30.  Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life 571 
and is associated with reduced disease control. Respir Med. 2011;105(6):930-938. 572 
doi:10.1016/j.rmed.2011.01.005 573 
31.  Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients’ 574 
satisfaction with their inhalers on treatment compliance and health status in COPD. Respir 575 
Med. 2014;108(2):358-365. doi:10.1016/j.rmed.2013.09.021 576 
32.  Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European 577 
Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. 578 
Am J Respir Crit Care Med. 2013;188(8):e13-64. doi:10.1164/rccm.201309-1634ST 579 




Legend to figures 581 
Figure 1: General flow of the APEX COPD Registry Delphi process 582 
Figure 2: Summary of the Delphi results for the APEX COPD registry 583 








  589 
• Round 1 
• Consolidation and 
finalisation of 
variables to be 
voted on. 
Feedback 
• Round 2 
• Vote on variables 
• Compilation and 
analysis of results 
Feedback 
• Round 3 
• Vote on variables 
• Compilation and 

























Table 2. Sample of the ‘Additional’ variable list from the APEX COPD Registry Delphi workbook Round 1 601 
 602 




Table 3. Final core variable list to be collected from A) the electronic health record (EHR), B) patient reported information and outcomes, and 604 
C) at the point of care 605 
Category* Sub-
category 
Variable Why is it important to collect? 
EHR variables (n=115) 
Demographics Height (In) • Required to predict lung function parameters.  
• Women and some ethnicities have smaller lungs, so these 
data could prospectively show risk of COPD at different 
























COPD diagnosis COPD • These are different phenotypes of COPD and when available 







Asthma • Asthma is the most common differential diagnosis and often 
co-exists with COPD (i.e. ACOS) 




Number pneumonia infections in past 2 yrs • May be indicators of unrecognized COPD exacerbations 
• May be side effect of ICS used in COPD management Number of other RTI in past 2 yrs 
Exacerbations No. moderate exacerbations in past year (also 
indicated by short course of Atb or OCS 
• Necessary to characterize severity, assess treatment 
effectiveness and monitor disease progression 
• May indicate a need for treatment escalation or treatment 
switch if the disease is poorly controlled.8  
No. severe exacerbations in past year (also 
indicated by hospitalization and course of 
Atb/OCS) 
Symptoms Wheezing • The most common symptom of COPD, after dyspnea 
Physiological 
measurements 











FEV1 post-bronchodilator • FEV1 provides information on severity of lung function 
impairment 
• Reversibility indicates the possibility of co-morbid asthma 
• FVC indicates restrictive issues 
• Oxygenation falls later in the disease. But treating with O2 is 
the only medication that affects prognosis 
• Blood eosinophilia a useful predictor of ICS response 
• CXR: useful for comorbidity assessment 
• CT: necessary for bronchiectasis and lung cancer screening 
• CV disease (and BP) is the major comorbidity 
FEV1 (pre-bronchodilator)/Predicted FEV1 (auto-
calculated) 
Predicted FVC (auto-calculated) 
FVC pre-bronchodilator 
FVC post-bronchodilator 
FVC (pre-bronchodilator)/Predicted FVC (auto-
calculated) 
Predicted FEV1/FVC ratio (auto-calculated) 
FEV1/FVC pre-bronchodilator (auto-calculated) 
FEV1/FVC post-bronchodilator (auto-calculated) 
Reversibility (%) 
PIFR 
Pulse oximetry (spO2, %) 
Full blood count 
Blood eosinophil count 
Chest X-ray 
CT scan 
Systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
6-minute walking test (ft) 
GOLD 
categorization 
GOLD 1-4 (auto-calculated) • To assess appropriateness of severity classification and its 





Allergy • Comorbidities most likely associated with asthma  
















Echo cardiogram • Signs of left and or right heart failure 









Pneumonia • A serious co-morbidity to COPD 
• A potential side effect of ICS use in COPD management 
Co-morbidities 
(cardiovascular) 
Angina pectoris/Heart disease/CHD • May require further evaluation/investigation 
• May affect outcomes 
• CHF also presents with dyspnea and is not always easy to tell 
apart 




























Bronchodilators SABA Required to: 
• Characterize treatments used 


















Steroids ICS • Assess appropriateness of treatment selection 
• Assess effectiveness of treatments and regimens (e.g. dual 
vs triple) 
• Assess ICS over use 
• Assess OCS burden 















Antibiotics • To evaluate effectiveness and exacerbation risk reduction  
Macrolides 
PDE inhibitors 






Smoking status • The most common etiology 
How many years has patient smoked? 
Pack years 




Smoking cessation advice given • To assess prognosis & determine which works best 
• Has the greatest capacity to influence the natural history of 
COPD. GOLD recommends to collect in order to monitor and 
encourage appropriate cessation interventions.8  
Referral to stop-smoking clinic/advisor 
Nicotine replacement therapy 
Drug therapy (e.g. Bupropion) 
Surgery Bullectomy 






Variable Why is it important to collect? 
Lung volume reduction coil • To identify best candidates and outcome for each of these 
surgical interventions Endobronchial Valve (EBV) 
Lung transplant 
Chest wall vibration 
Specialist 
referral 
Palliative care • To consider respiratory evaluations by non-respiratory or 








Other therapies Pulmonary rehabilitation (PR) • To assess availability and efficacy 
• PR is critically important for best outcomes Oxygen therapy 
Home nebulizer 
Ventilatory support 













Asthma • Asthma is the most common differential diagnosis and often 
co-exists with COPD (i.e. ACOS) 




No. of pneumonia infections in past 2 yrs • Effect on disease outcome  
• Effect on treatment outcome 
No. of other RTI in past 2 yrs  
Exacerbations No. of moderate exacerbations in past year (also 
indicated by course of Atb/OCS) 
• Key patient outcome 




















• Indication of a need for treatment escalation or treatment 
switch.8  
No. of severe exacerbations in past year (also 
indicated by emergency hospitalization and 




Modified MRC Dyspnea Scale • Key patient outcome (validated scales) 
• Indicator of severity, disease progression and effectiveness 
of treatment.28  
COPD Assessment Test 
Risk factors Childhood respiratory infections • Little- and well-known risk factors for COPD development 
• History of severe childhood respiratory infection has been 
associated with reduced lung function & increased 
respiratory symptoms in adulthood.29  
Occupational exposure 
Tobacco exposure 
Age of onset of respiratory symptoms yrs 
Family history of COPD 
Co-morbidities 
(mental) 


















Spacer with MDI • Good inhaler technique is critical to get medication where it 
is needed. 
• Poor technique and poor adherence are commonly 
associated with poor symptom control in COPD.30  
• Patient satisfaction & preference are often not collected. 
Patient satisfaction with treatment may influence 
adherence.22,31  
Inhaler technique training 
Inhaler use/adherence 
Test of Adherence to Inhalers (TAI) questionnaire 
Inhaler satisfaction questionnaire 
Treatment side 
effects 
Oral • An important patient outcome which may impact treatment 
adherence and continuance Physiological 
Smoking Smoking status • Important for prognosis 
Date ceased smoking (if applicable) 
How many cigarettes smoked per day? 















Vaccinations Influenza • A preventable issue 
Smoking 
cessation 
Desire to quit smoking • To assess motivation to quit 
• To encourage motivational interviewing Tried to quit in the past 




COPD education • To assess available, utility and the benefits (if any) of action 
plans 
• Education & self-management interventions can help 
improve the physical & psychological condition of COPD 
patients & promote long-term adherence to health-
enhancing behaviors.32 
COPD self-management plan 
Patient’s use of COPD self-management plan 
Other therapies Pulmonary rehabilitation • To assess availability and efficacy 
• PR is critically important for best outcomes 
PoC Variables (n=5)  
Disease 
monitoring 
Exacerbations No. of moderate exacerbations in past year (also 
indicated by course of Atb/OCS) 
• Key patient outcome 
• An indicator of severity, disease progression and 
effectiveness of treatment 
No. severe exacerbations in past year (also 
indicated by emergency hospitalization and 




FEV1 post-bronchodilator • An indicator of illness progression 
• To unmask other illnesses 





Inhaler technique assessment • To assess impact on treatment efficacy and to better select 
device if treatment or device change required. This might 
include observed technique and PIFR assessment if felt 
clinically necessary   
AATD: Alpha-1 antitrypsin deficiency; Atb: antibiotic; BMI: body mass index; BP: blood pressure; CHD: coronary heart disease; COPD: Chronic Obstructive 
Pulmonary Disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GERD; gastroesophageal reflux disease; GOLD: Global 






Variable Why is it important to collect? 
leukotriene receptor antagonist; MDI: metered dose inhaler; MRC: Medical Research Council; OCS: oral corticosteroid; PDE: phosphodiesterase; PIFR: 
peak inspiratory flow rate; RTI: respiratory tract infection; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist 
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Supplementary Table E1. Delphi panel members 
Member Primary area(s) of 
expertise 
Country 
Alvaro Aranda Specialist Puerto Rico 
Ku-Lang Chang Primary care USA 
Chester Fox Primary care USA 
Gokul Gopalan Research USA 
MeiLan Han Specialist USA 
Alan Kaplan Primary care, specialist Canada 
Janwillem Kocks Research, primary care Netherlands 
Catherine Mahle Research USA 
Barry Make Specialist USA 
Wilson Pace Research, primary care USA 
David Price Research, primary care UK/Singapore 
Neil Skolnik Primary care USA 






Supplementary Table E2 APEX COPD registry Operational Management Group 
Member  
Victoria Carter Operational lead 
Chelsea Edwards Research lead 
Gokul Gopalan Steering committee member 
Janwillem Kocks Steering committee member 
Wilson Pace Steering committee member 
David Price Steering committee member 






Supplementary Table E3. Categorization of potential APEX COPD registry variables  
Category Number of variables listed 
Demographics 6 
Disease monitoring 
 COPD diagnosis 
 Differential diagnosis 
 Respiratory infections 
 Exacerbations 
 Symptoms 
 Health status (quality of life) 
 Physiological measurements 
 GOLD categorization 
 Risk factors 


















 Inhaler management 
 Co-morbidity treatments 
 Other treatments 
 Treatment side effects 
 Smoking 
 Vaccinations 
 Smoking cessation 
 Education & self-management 
 Surgery 
 Specialist referral 




















Supplementary Table E4. Delphi Round 1 results summary  
R1 variable summary Number Consensus criteria Remarks 
Potential variables    
Total number of 
variables 
189  
All variables entered in 
R2 with additional 
recommendations. 
Consensus to keep 149 >66% 













Supplementary Table E5. Delphi Round 2 results summary 




All potential variables 
Part A: Keep, undecided or exclude 
Total number of variables 195   
Consensus to keep 170 ≥66% 
Included in final core variable list  
if consensus was reached for collection 
by EHR, patient reported information 
outcomes, or at the point of care. 
Undecided 20 40-65% 
Included in R3 at the discretion of the 
Operational Management Group* 
Consensus to exclude 5 <40% Excluded from final core variable list 
Part B: from which data source – EHR, PRI/PRO or PoC? 
Potential variables for collection from EHR 
Total number of variables 170   
Consensus to keep 115 ≥66% Included in final core variable list 
Undecided 48 40-65% Entered into R3 
Consensus to exclude 7 <40% Excluded from final core variable list 
Potential variables for collection as patient reported and information and outcomes 
Total number of variables 170   
Consensus to keep 16 ≥66% Included in final core variable list 
Undecided 57 40-65% Entered in R3 
Consensus to exclude 97 <40% Excluded from final core variable list 
Potential variables for collection at the point of care 
Total number of variables 170   
Consensus to keep 0 ≥66% Included in final core variable list 
Undecided 9 40-65% Entered in R3 




*4 undecided variables were included in R3 for collection as patient reported information and 
outcomes, remaining variables were excluded from the final core variable list. 
**With the exception of one variable, included in R3 at the discretion of the APEX COPD registry 







Supplementary Table E6. Delphi Round 3 results summary 
R3 variable summary Number Consensus criteria Remarks 
Remain potential variables for collection as patient reported and information and outcomes 
Total number of 
variables 
61   
Consensus to keep 13 ≥66% 
Included in the final core 
variable list 
Undecided 27 40-65% 
Included in the final core 
variable list at the 






Excluded from final core 
variable list 
Remaining potential variables for collection at the point of care 
Total number of 
variables 
10   
Consensus to keep 2 ≥66% 
Included in the final core 
variable list 
Undecided 3 40-65% 
Included in the final core 
variable list at the 






Excluded from final core 
variable list 
*4 undecided variables were included the final core variable list. 
**All undecided variables were included the final core variable list. 
 
